FAQ published on October 10, 2018
In this activity, Dr. Alison Moskowitz explains the importance of determining prognostic risk when treating patients who are newly diagnosed with Hodgkin lymphoma and what tools clinicians should use.
FAQ published on July 25, 2018
Dr. Anas Younes discusses the immune-related toxicities clinicans should be mindful of when prescribing a new checkpoint inhibitor and what you can do to help treat these side effects.
FAQ published on December 26, 2017
In this activity, Dr. Matasar will explain how to evaluate a patient's response to immunotherapy in the relapse and first-line setting.
FAQ published on December 26, 2017
Join Dr. Matasar as he discusses how to decide if a newly diagnosed Hodgkin lymphoma patient needs to have a bone marrow biopsy as part of their initial workup.
FAQ published on December 26, 2017
In this activity, Dr. Matasar provides an update from the ASH 2017 Annual Meeting on immunotherapy in the treatment of Hodgkin lymphoma.
FAQ published on December 8, 2017
Join Dr. Ansell as he will discuss the two main issues in today's management of front-line classical Hodgkin lymphoma, including bleomycin and radiation therapy.
FAQ published on November 13, 2017
Join Dr. John Sweetenham as he discusses the role of brentuximab vedotin as first-line salvage therapy prior to ASCT and ongoing studies using BV in combination with other conventional regimens.
FAQ published on October 9, 2017
In this activity, Dr Sweetenham will discuss the current options for patients with HL who have relapsed after autologous stem cell transplantation.
FAQ published on September 29, 2017
Dr. Ansell discusses what future changes may lie ahead beyond current treatment options in frontline therapy, focusing on new clinical trial results with brentuximab vedotin.
FAQ published on September 11, 2017
Join Dr. John Sweetenham as he discusses the risk factors that may predict ASCT outcomes including, primary refractory disease and extranodal disease.
Page 1 of 7
Results 1 - 10 of 63

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2020 MediCom Worldwide, Inc. All rights reserved